CT-95
Phase 1RecruitingDevelopment Stage
Mesothelin-Expressing Tumors
Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer, Malignant Pleural Mesothelioma, Advanced, Malignant Peritoneal Mesothelioma, Advanced, Pancreatic Adenocarcinoma Advanced or Metastatic, Lung Adenocarcinoma Metastatic, Cholangiocarcinoma Advanced, Cholangiocarcinoma Non-resectable, Mesothelin-expressing Advanced Cancers, Mesothelin-positive Advanced Malignant Solid Tumors, Colorectal Cancer
Mar 31, 2025 → Dec 1, 2028
About CT-95
CT-95 is a phase 1 stage product being developed by Context Therapeutics for Mesothelin-Expressing Tumors. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06756035. Target conditions include Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer, Malignant Pleural Mesothelioma, Advanced.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06756035 | Phase 1 | Recruiting |
Competing Products
1 competing product in Mesothelin-Expressing Tumors
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ZW171 | Zymeworks | Phase 1 | 28 |